Bank CEOs meet with Trump to discuss Fannie Mae and Freddie Mac - Bloomberg
Thomas J. Klima, the Chief Commercial and Operating Officer of bluebird bio, Inc. (NASDAQ:BLUE), recently sold shares of the company’s common stock. According to a recent SEC filing, Klima disposed of 122 shares on February 3, 2025, at an average price of $7.3925 per share, amounting to a total transaction value of approximately $901.
These shares were sold to cover tax withholding obligations related to the vesting of Restricted Stock Units. Following this transaction, Klima holds 8,378 shares directly. It’s important to note that the number of shares reflects a 1-for-20 reverse stock split implemented by bluebird bio in December 2024. With a market capitalization of just $67.37 million, InvestingPro subscribers can access 13 additional key insights and a comprehensive Pro Research Report about this volatile biotech stock.
In other recent news, Bluebird Bio has been the subject of several analyst adjustments. RBC Capital Markets significantly lowered its price target for Bluebird Bio shares from $80.00 to $8.00 due to severe adverse events linked to the company’s treatments. Despite this, the firm maintained a Sector Perform rating on Bluebird Bio’s stock. Likewise, Baird adjusted its price target on Bluebird Bio’s shares to $54 from $120, citing anticipated near-term dilution. However, Baird maintained an Outperform rating, expressing belief in the significant potential of the company’s lentiviral vector (LVV)-based cell therapies.
BofA Securities downgraded Bluebird Bio’s stock from Buy to Neutral and reduced the price target to $0.50 from $3.00 following the company’s third-quarter update. The firm cited slower ramp-up and lower peak revenue expectations for Bluebird Bio’s key product, Lyfgenia, as reasons for the downgrade. JPMorgan also downgraded Bluebird Bio’s shares from Neutral to Underweight after the company’s third-quarter financial results revealed a loss per share of $0.31 and revenue of $10.6 million, falling short of the $18.3 million consensus estimate.
Lastly, during its Third Quarter 2024 Earnings Call, Bluebird Bio reported an increase in patient starts and a path to cash flow breakeven by the second half of 2025, assuming additional cash resources are secured. Despite a decline in Q3 revenue to $10.6 million from $16.1 million in Q2, the company forecasts a rebound to at least $25 million in Q4.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.